Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Current Helicobacter Pylori infection preferred treatment involves; proton pump inhibitor
(PPI)-based triple or qudrable regimens. Omeprazole, Amoxicillin, and Clarithromycin is one
of a global standard care for confirmed H.pylori infection . Metronidazole (MTZ) is used
instead of Amoxicillin or Clarithromycin in cases of allergy or resistance .
However, a recent study based on the Maastricht III guidelines, indicated that treatment with
a PPI-based triple regimen as first-line therapy will fail in ~30% of patients on an
intention-to-treat (ITT) basis, and will fail in ~ 50 % of patients who treated with
PPI-based triple regimen with Metronidazole. This treatment resistance is also an issue
warranting the investigation of other agents. Helicobacter pylori infection has become
increasingly resistant to traditional first-line treatment regimens because of emerging
antibiotic resistance coupled with poor patient compliance with completing the treatment
course that decrease H. pylori eradication rates. So there is a considerable interest in
evaluating new antibiotic combinations and regimens .